Education
About Us
Working with TipRanks
Follow Us
Kazia Therapeutics Limited (KZIA)
NASDAQ:KZIA
Total Valuation
Kazia Therapeutics has a market cap or net worth of $10.40M. The enterprise value is $28.64M.
Market Cap$10.40M
Enterprise Value$28.64M
Share Statistics
Kazia Therapeutics has 1,117,859 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,117,859
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Kazia Therapeutics’s return on equity (ROE) is 2.67 and return on invested capital (ROIC) is 0.00%.
Return on Equity (ROE)2.67
Return on Assets (ROA)-1.24
Return on Invested Capital (ROIC)0.00%
Return on Capital Employed (ROCE)0.00
Revenue Per Employee256.44K
Profits Per Employee-2.98M
Employee Count9
Asset Turnover0.11
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Kazia Therapeutics is -0.29. Kazia Therapeutics’s PEG ratio is <0.01.
PE Ratio-0.29
PS Ratio0.00
PB Ratio0.27
Price to Fair Value-0.78
Price to FCF-0.21
Price to Operating Cash Flow-0.21
PEG Ratio<0.01
Income Statement
In the last 12 months, Kazia Therapeutics had revenue of 2.31M and earned -26.78M in profits. Earnings per share was -55.85.
Revenue2.31M
Gross Profit2.31M
Operating Income0.00
Pretax Income-27.05M
Net Income-26.78M
EBITDA-26.77M
Earnings Per Share (EPS)-55.85
Cash Flow
In the last 12 months, operating cash flow was -9.58M and capital expenditures 0.00, giving a free cash flow of -9.58M billion.
Operating Cash Flow-9.58M
Free Cash Flow-9.58M
Free Cash Flow per Share-8.57
Dividends & Yields
Kazia Therapeutics pays an annual dividend of $156.513, resulting in a dividend yield of ―
Dividend Per Share$156.513
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.35
52-Week Price Change-19.13%
50-Day Moving Average4.13
200-Day Moving Average12.44
Relative Strength Index (RSI)81.70
Average Volume (3m)1.73M
Important Dates
Kazia Therapeutics upcoming earnings date is Aug 28, 2025, TBA Not Confirmed.
Last Earnings DateFeb 19, 2025
Next Earnings DateAug 28, 2025
Ex-Dividend DateJan 28, 2013
Financial Position
Kazia Therapeutics as a current ratio of 0.24, with Debt / Equity ratio of 14.90%
Current Ratio0.24
Quick Ratio0.24
Debt to Market Cap0.08
Net Debt to EBITDA0.04
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Kazia Therapeutics has paid -271.00K in taxes.
Income Tax-271.00K
Effective Tax Rate0.01
Enterprise Valuation
Kazia Therapeutics EV to EBITDA ratio is -145.88, with an EV/FCF ratio of -407.55.
EV to Sales1.69K
EV to EBITDA-145.88
EV to Free Cash Flow-407.55
EV to Operating Cash Flow-407.55
Balance Sheet
Kazia Therapeutics has $1.66M in cash and marketable securities with AU$634.00K in debt, giving a net cash position of -$1.02M billion.
Cash & Marketable Securities$1.66M
Total DebtAU$634.00K
Net Cash-$1.02M
Net Cash Per Share-$0.92
Tangible Book Value Per Share-$0.11
Margins
Gross margin is 100.00%, with operating margin of 0.00%, and net profit margin of -1160.23%.
Gross Margin100.00%
Operating Margin0.00%
Pretax Margin-1171.97%
Net Profit Margin-1160.23%
EBITDA Margin-1159.71%
EBIT Margin-1240.68%
Analyst Forecast
The average price target for Kazia Therapeutics is $15.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$15.00
Price Target Upside61.29% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast19.58%